Form 8-K - Current report:
SEC Accession No. 0000950170-22-003001
Filing Date
2022-03-07
Accepted
2022-03-07 16:11:28
Documents
14
Period of Report
2022-03-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K elym-20220307.htm   iXBRL 8-K 70823
2 EX-99.1 elym-ex99_1.htm EX-99.1 262453
3 GRAPHIC img171973770_0.jpg GRAPHIC 60643
  Complete submission text file 0000950170-22-003001.txt   561171

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT elym-20220307_lab.xml EX-101.LAB 19058
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT elym-20220307.xsd EX-101.SCH 2485
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT elym-20220307_pre.xml EX-101.PRE 11999
8 EXTRACTED XBRL INSTANCE DOCUMENT elym-20220307_htm.xml XML 4902
Mailing Address 23515 NE NOVELTY HILL ROAD SUITE B221 #125 REDMOND WA 98053
Business Address 23515 NE NOVELTY HILL ROAD SUITE B221 #125 REDMOND WA 98053 425-276-2300
Eliem Therapeutics, Inc. (Filer) CIK: 0001768446 (see all company filings)

EIN.: 832273741 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40708 | Film No.: 22718115
SIC: 2834 Pharmaceutical Preparations